行情

DXCM

DXCM

德康医疗
NASDAQ

实时行情|Nasdaq Last Sale

230.79
-3.62
-1.54%
盘后: 230.50 -0.3 -0.13% 19:30 01/17 EST
开盘
236.19
昨收
234.41
最高
236.81
最低
230.26
成交量
53.08万
成交额
--
52周最高
242.14
52周最低
107.44
市值
211.24亿
市盈率(TTM)
-118.8843
分时
5日
1月
3月
1年
5年

分析师评级

18位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

DXCM 新闻

  • 莆田系资本新局 27岁“林氏二代”入主莎普爱思
  • 金融界.1天前
  • 莆田系接盘莎普爱思 白内障“神药”能重出江湖吗?
  • 华夏时报.2天前
  • Here's Why DexCom (DXCM) is a Great Momentum Stock to Buy
  • Zacks.2天前
  • Dentsply (XRAY) Soars to 52-Week High, Time to Cash Out?
  • Zacks.2天前

更多

所属板块

医疗设备、用品及经销
+0.07%
医疗设备和用品
+0.29%

热门股票

名称
价格
涨跌幅

DXCM 简况

Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company's products consist of DexCom G4 PLATINUM and DexCom G5 Mobile. The Company is commercializing its fifth generation CGM system. The Company's markets DexCom G4 PLATINUM under a Conformite Europeenne Marking (CE Mark), in the European Union, Australia, New Zealand and the countries in Asia and Latin America, and in the United States with approval from the United States Food and Drug Administration (FDA). The DexCom G4 PLATINUM with Share remote monitoring system uses a wireless connection between a patient's receiver and an application on the patient's iPhone, iPod touch, or iPad to transmit glucose information to applications on the mobile devices of designated recipients (followers).
展开

Webull提供DexCom, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。